Massare
Michael Massare, Mt. Airy, MD US
Patent application number | Description | Published |
---|---|---|
20100239617 | MODIFIED RSV F PROTEINS AND METHODS OF THEIR USE - The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection. | 09-23-2010 |
20130039938 | HIGHLY EFFICIENT INFLUENZA MATRIX (M1) PROTEINS - This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs. | 02-14-2013 |
20150307849 | HIGHLY EFFICIENT INFLUENZA MATRIX (M1) PROTEINS - This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs. | 10-29-2015 |
Michael Massare, Rockville, MD US
Patent application number | Description | Published |
---|---|---|
20130122032 | RECOMBINANT NANOPARTICLE RSV F VACCINE FOR RESPIRATORY SYNCYTIAL VIRUS - The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection. | 05-16-2013 |
Michael Massare, Gaithersburg, MD US
Patent application number | Description | Published |
---|---|---|
20150306207 | RECOMBINANT NANOPARTICLE RSV F VACCINE FOR RESPIRATORY SYNCYTIAL VIRUS - The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection. | 10-29-2015 |
Michael J. Massare, Mt. Airy, MD US
Patent application number | Description | Published |
---|---|---|
20140271697 | ENHANCED EXPRESSION OF PICORNAVIRUS PROTEINS - The disclosure provides fusion proteins containing N-terminal signal peptides fused to immunogenic polypeptides. The immunogenic polypeptides may be from viruses, bacteria, or fungi. The disclosure also provides elevated expression of the immunogenic polypeptides using the N-terminal signal peptide. The N-terminal signal peptides enhance synthesis of the protein, particularly where the protein is neither a secretory nor a transmembrane peptide. The fusion proteins may be used to diagnose disease and to induce immune responses. | 09-18-2014 |
20140294879 | MODIFIED RSV F PROTEINS AND METHODS OF THEIR USE - The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection. | 10-02-2014 |
20150265698 | MODIFIED RSV F PROTEINS AND METHODS OF THEIR USE - The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection. | 09-24-2015 |
20150266930 | MODIFIED RSV F PROTEINS AND METHODS OF THEIR USE - The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection. | 09-24-2015 |
Mike Massare, Rockville, MD US
Patent application number | Description | Published |
---|---|---|
20080233150 | RESPIRATORY SYNCYTIAL VIRUS-VIRUS LIKE PARTICLE (VLPS) - The present invention discloses and claims virus like particles (VLPs) that express and/or contains RSV proteins. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing immunity to infections, including RSV. | 09-25-2008 |